NEW HAVEN, Conn. — May 5, 2026 — Leads & Copy — Invivyd, Inc. (Nasdaq: IVVD) announced today that on May 1, 2026, it granted 17 newly hired non-executive employees options to purchase an aggregate of 731,000 shares of its common stock as a material inducement for their employment.
The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.
The options have a per share exercise price of $1.52, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan.
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform designed to assess, monitor, develop, and adapt to create best-in-class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates.
Source: Invivyd, Inc.
